Anika Therapeutics (NASDAQ: ANIK) launched its injectable hyaluronic acid (HA) enhanced bone repair therapy, TACTOSET, in the U.S. for the treatment of bone voids and other bone defects.
TACTOSET is an injectable, HA-enhanced, calcium phosphate bone substitute material. It is indicated for bone defects caused by trauma or age-related degeneration in regions of the skeletal system that are not intrinsic to the stability of bony structure.
TACTOSET is the first product to launch under Anika’s U.S.-based hybrid commercial model.
“We believe our hybrid commercial model provides us with a direct line of sight into the market, enabling Anika to achieve rapid market penetration with TACTOSET, while avoiding the significant investment associated with building a large direct sales force internally,” Joseph Darling, Anika’s president and CEO, said in a statement.
“Additionally, we expect our hybrid model to provide the ability to launch in various phases and to scale where appropriate as we introduce products across multiple categories in the orthopedic segment,” he added.